BR0016231A - Composição compreendendo enzima com capacidade de clivar uma ligação que efetua a liberação de uma proteìna ou carboidrato de superfìcie celular para ser usada no tratamento de infecções - Google Patents

Composição compreendendo enzima com capacidade de clivar uma ligação que efetua a liberação de uma proteìna ou carboidrato de superfìcie celular para ser usada no tratamento de infecções

Info

Publication number
BR0016231A
BR0016231A BR0016231-0A BR0016231A BR0016231A BR 0016231 A BR0016231 A BR 0016231A BR 0016231 A BR0016231 A BR 0016231A BR 0016231 A BR0016231 A BR 0016231A
Authority
BR
Brazil
Prior art keywords
carbohydrate
releases
cell surface
treatment
surface protein
Prior art date
Application number
BR0016231-0A
Other languages
English (en)
Other versions
BRPI0016231B1 (pt
BRPI0016231B8 (pt
Inventor
Lin Liu
Humg-Yu Hsiao
Douglas W Fodge
David M Anderson
Original Assignee
Chemgen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22617824&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0016231(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chemgen Corp filed Critical Chemgen Corp
Publication of BR0016231A publication Critical patent/BR0016231A/pt
Publication of BRPI0016231B1 publication Critical patent/BRPI0016231B1/pt
Publication of BRPI0016231B8 publication Critical patent/BRPI0016231B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/189—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04011—Phosphoinositide phospholipase C (3.1.4.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01078—Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Polymers & Plastics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Animal Husbandry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

"COMPOSIçãO COMPREENDENDO ENZIMA COM CAPACIDADE DE CLIVAR UMA LIGAçãO QUE EFETUA A LIBERAçãO DE UMA PROTEìNA OU CARBOIDRATO DE SUPERFìCIE CELULAR PARA SER USADA NO TRATAMENTO DE INFECçõES". Enzimas de uma classe particular, caracterizadas pela capacidade de clivar uma ligação que efetua a liberação de uma proteína ou carboidrato de superfície celular, que não contêm um agente antiinfecção, apresentam significativa atividade antiinfecciosa. Sob administração oral, essas enzimas são eficazes, por exemplo, no tratamento de infecções do trato digestivo em humanos e em animais. Posteriormente, há benefícios de uma taxa de crescimento, eficácia de alimento, e saúde gerais significativamente aumentadas.
BRPI0016231A 1999-12-10 2000-12-08 composições compreendendo enzimas úteis para tratar ou melhorar os riscos de infecção do trato digestivo BRPI0016231B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16993599P 1999-12-10 1999-12-10
PCT/US2000/033466 WO2001041785A2 (en) 1999-12-10 2000-12-08 Enzyme treatment for infection

Publications (3)

Publication Number Publication Date
BR0016231A true BR0016231A (pt) 2003-06-24
BRPI0016231B1 BRPI0016231B1 (pt) 2016-10-04
BRPI0016231B8 BRPI0016231B8 (pt) 2021-05-25

Family

ID=22617824

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0016231A BRPI0016231B8 (pt) 1999-12-10 2000-12-08 composições compreendendo enzimas úteis para tratar ou melhorar os riscos de infecção do trato digestivo

Country Status (31)

Country Link
US (2) US6780628B2 (pt)
EP (1) EP1239872B1 (pt)
JP (1) JP4871473B2 (pt)
KR (1) KR100639746B1 (pt)
CN (3) CN101327320A (pt)
AR (2) AR026764A1 (pt)
AT (1) ATE481981T1 (pt)
AU (1) AU782831B2 (pt)
BR (1) BRPI0016231B8 (pt)
CA (1) CA2394856C (pt)
CL (1) CL2008000057A1 (pt)
CO (1) CO5280226A1 (pt)
CR (1) CR6674A (pt)
CZ (1) CZ304925B6 (pt)
DE (1) DE60045010D1 (pt)
DK (1) DK1239872T3 (pt)
ES (1) ES2353371T3 (pt)
HU (1) HU230301B1 (pt)
IL (2) IL150048A0 (pt)
IN (1) IN247731B (pt)
MX (1) MX264033B (pt)
MY (1) MY124714A (pt)
NZ (1) NZ519404A (pt)
PH (1) PH12000003381B1 (pt)
PL (1) PL203054B1 (pt)
PT (1) PT1239872E (pt)
RU (1) RU2272419C2 (pt)
SK (1) SK287956B6 (pt)
TW (1) TWI255189B (pt)
UA (1) UA78486C2 (pt)
WO (1) WO2001041785A2 (pt)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
US7247299B2 (en) * 2002-11-27 2007-07-24 Kemin Industries, Inc. Antimicrobial compounds from Bacillus subtilis for use against animal and human pathogens
US8394379B2 (en) * 2003-05-15 2013-03-12 Iogenetics, Llc Targeted cryptosporidium biocides
US7566447B2 (en) * 2003-05-15 2009-07-28 Iogenetics, Llc Biocides
US20050014932A1 (en) * 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US8703134B2 (en) 2003-05-15 2014-04-22 Iogenetics, Llc Targeted cryptosporidium biocides
US8431123B2 (en) 2003-07-14 2013-04-30 Cls Therapeutics Limited Method for treating systemic bacterial, fungal and protozoan infection
US8388951B2 (en) 2003-07-14 2013-03-05 Cls Therapeutics Limited Method for treating systemic DNA mutation disease
US8710012B2 (en) 2003-07-14 2014-04-29 Cls Therapeutics Limited Method for treating oncological diseases
AU2005332655A1 (en) * 2004-10-20 2006-12-14 Iogenetics, Llc Biocides
EP1880733A4 (en) 2005-04-25 2009-08-12 Genkin Dmitry Dmitrievich METHOD FOR EXTENDING THE LIFE OF A HUMAN AND ANIMALS
BRPI0620155B1 (pt) * 2005-12-15 2015-07-21 Lilly Co Eli Composição adequada para administração oral a um animal compreendendo uma enzima redutora de estresse imunológico em um veículo aceitável por via oral
JP5372769B2 (ja) 2006-11-28 2013-12-18 シーエルエス セラピューティック リミティド 組織の細胞外間隙においてデオキシリボ核酸の量が増量することに関連するヒトの病気の治療方法及び該方法を実施するための医薬製剤
EP2164862B1 (en) * 2007-06-08 2015-07-22 Australian Poultry CRC Pty Ltd Clostridial toxin netb
JP5427789B2 (ja) * 2007-12-20 2014-02-26 ダニスコ・ユーエス・インク バイオフィルムの酵素的予防及び制御
ES2645062T3 (es) * 2008-02-08 2017-12-04 Prothera, Inc. Inhibición y tratamiento de biopelículas gastrointestinales
PL2814331T3 (pl) 2012-02-16 2019-04-30 Elanco Inc Sposoby i kompozycje do zmniejszenia wpływu odpadów zwierzęcych na środowisko
US10617743B2 (en) 2014-06-19 2020-04-14 Cls Therapeutics Limited Method to improve safety and efficacy of anti-cancer therapy
TWI656872B (zh) 2014-11-13 2019-04-21 美商益農美國公司 甲基鹽黴素於豬飼料中之抗病毒效果
RU2726131C2 (ru) 2015-05-22 2020-07-09 Дмитрий Дмитриевич Генкин Внеклеточная днк в качестве терапевтической мишени при нейродегенерации
CN106119221A (zh) * 2016-06-28 2016-11-16 浙江省农业科学院 磷脂酰肌醇特异性磷脂酶c基因、载体、工程菌及应用
CN106318925B (zh) * 2016-08-19 2021-04-02 浙江省农业科学院 利用枯草芽孢杆菌高效表达pi-plc基因的方法
CN106615691B (zh) * 2016-10-11 2019-07-02 上海国龙生物技术集团有限公司 一种抗感染酶复合剂及其在饲料中的应用
US10501730B2 (en) * 2017-05-30 2019-12-10 Ab Enzymes Oy Mannanase variants
AU2019209770A1 (en) 2018-01-16 2020-09-03 Cls Therapeutics Limited Treatment of diseases by liver expression of an enzyme which has a deoxyribonuclease (DNase) activity
US20210011027A1 (en) * 2018-03-02 2021-01-14 Evonik Operations Gmbh In vitro method for detecting intestinal barrier failure in animals by determining ovotransferrin
RU2720471C1 (ru) * 2019-03-21 2020-04-30 Федеральное Государственное бюджетное научное учреждение "Федеральный научный центр биологических систем и агротехнологий российской академии наук" Кормовая добавка для цыплят-бройлеров

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
JPS5534039A (en) 1978-08-30 1980-03-10 Hiroo Ikezawa Preparation of phsophatidylinositol phospholipase c from bacillus thuringiensis
US4891319A (en) 1985-07-09 1990-01-02 Quadrant Bioresources Limited Protection of proteins and the like
US4877738A (en) 1986-07-25 1989-10-31 Wisconsin Alumni Research Foundation Biological control of damping off and root rot and inoculum preparation therefor
US5049379A (en) 1987-07-27 1991-09-17 Wisconsin Alumni Research Foundation Fungicidal toxin and method and inoculum for controlling root rot and damping off
JPH0338530A (ja) * 1989-07-03 1991-02-19 Ajinomoto Co Inc 抗真菌剤
US5487897A (en) * 1989-07-24 1996-01-30 Atrix Laboratories, Inc. Biodegradable implant precursor
ATE161395T1 (de) * 1990-05-29 1998-01-15 Chemgen Corp Hemicellulasezusatz geeignet zum erhöhen des energiewirkungsgrads von hemicellulose enthaltenden nahrungsmitteln und tierfutter
EP0477739A3 (en) * 1990-09-27 1992-12-09 F. Hoffmann-La Roche Ag Glycosyl-phosphatidylinositol-specific phospholipase d
JPH07184642A (ja) * 1993-12-27 1995-07-25 Toagosei Co Ltd ホスホリパーゼｃの生産方法
EP0743017B1 (en) * 1995-05-15 2004-09-29 DSM IP Assets B.V. Application of phospholipases in animal feed
NL1003096C2 (nl) * 1995-05-15 1996-11-19 Gist Brocades Bv Application of phospholipases in animal feed.
JPH08332032A (ja) * 1995-06-12 1996-12-17 Showa Denko Kk 動物経口物用酵素剤及びその用途
JP3914585B2 (ja) * 1995-10-19 2007-05-16 イーエヌ大塚製薬株式会社 マクロファージ一酸化窒素産生亢進剤
US6162473A (en) * 1996-05-03 2000-12-19 Chemgen Corporation Hemicellulase use in feeds with low caloric content
CN1092495C (zh) * 1996-05-03 2002-10-16 开姆根有限公司 半纤维素酶在低热焓饲料中的应用
JPH1045581A (ja) * 1996-07-29 1998-02-17 Hideyo Yamaguchi 好中球機能低下抑制剤又は感染防御剤
EP0948608A1 (en) * 1996-10-31 1999-10-13 Novo Nordisk A/S Novel phospholipase, production and use thereof
AU753232B2 (en) 1998-10-15 2002-10-10 Dsm N.V. Antimicrobial enzymes in animal feed
UA78486C2 (uk) 1999-12-10 2007-04-10 Хемджен Корпорейшн Композиція для перорального введення птахам та тваринам для лікування або зниження ризику інфекції травного тракту (варіанти), її застосування (варіанти) та спосіб лікування або зниження ризику інфекцій травного тракту (варіанти)
US20020116028A1 (en) * 2001-02-20 2002-08-22 Wilson Greatbatch MRI-compatible pacemaker with pulse carrying photonic catheter providing VOO functionality

Also Published As

Publication number Publication date
BRPI0016231B1 (pt) 2016-10-04
SK8262002A3 (en) 2002-12-03
PL203054B1 (pl) 2009-08-31
US20020048576A1 (en) 2002-04-25
KR100639746B1 (ko) 2006-10-30
IL150048A (en) 2016-09-29
MY124714A (en) 2006-06-30
CR6674A (es) 2007-02-22
PH12000003381B1 (en) 2010-04-16
CO5280226A1 (es) 2003-05-30
DE60045010D1 (de) 2010-11-04
CN102172262A (zh) 2011-09-07
JP4871473B2 (ja) 2012-02-08
MX264033B (es) 2009-01-22
ES2353371T3 (es) 2011-03-01
IN247731B (pt) 2011-05-13
KR20020069204A (ko) 2002-08-29
SK287956B6 (sk) 2012-07-03
TWI255189B (en) 2006-05-21
UA78486C2 (uk) 2007-04-10
HUP0203402A3 (en) 2004-12-28
AR089799A2 (es) 2014-09-17
CA2394856A1 (en) 2001-06-14
CN1433319A (zh) 2003-07-30
HUP0203402A2 (hu) 2003-02-28
IN2002DE00585A (pt) 2009-03-20
US6780628B2 (en) 2004-08-24
PL356175A1 (en) 2004-06-14
CN101327320A (zh) 2008-12-24
RU2272419C2 (ru) 2006-03-27
ATE481981T1 (de) 2010-10-15
US7723091B2 (en) 2010-05-25
CZ20022007A3 (cs) 2002-11-13
WO2001041785A3 (en) 2002-01-24
DK1239872T3 (da) 2010-10-25
HU230301B1 (hu) 2015-12-28
PT1239872E (pt) 2010-12-03
US20040223961A1 (en) 2004-11-11
AU782831B2 (en) 2005-09-01
EP1239872A2 (en) 2002-09-18
CN102172262B (zh) 2014-03-05
EP1239872B1 (en) 2010-09-22
CL2008000057A1 (es) 2008-03-14
MXPA02005735A (es) 2003-10-14
BRPI0016231B8 (pt) 2021-05-25
JP2003520207A (ja) 2003-07-02
AU2577601A (en) 2001-06-18
AR026764A1 (es) 2003-02-26
CA2394856C (en) 2011-05-10
CZ304925B6 (cs) 2015-01-28
WO2001041785A2 (en) 2001-06-14
IL150048A0 (en) 2002-12-01
NZ519404A (en) 2004-05-28

Similar Documents

Publication Publication Date Title
BR0016231A (pt) Composição compreendendo enzima com capacidade de clivar uma ligação que efetua a liberação de uma proteìna ou carboidrato de superfìcie celular para ser usada no tratamento de infecções
BR0007166A (pt) Método para aumentar a atividade dos animais de estimação
ATE243029T1 (de) Transdermales system zur verabreichung durch entepithelisierte haut
DK0671942T3 (da) Farmaceutisk præparat omfattende en beta-lactamantibiotikumnedbrydende forbindelse og anvendelse deraf
EP0382355A3 (en) Growth promoting agent for bacteria containing pullulan and/or dextran
DE60122672D1 (de) Zusammensetzung zur intestinalen verabreichung
IT1307850B1 (it) Composizione farmaceutica a base di fermenti lattici e carboidratinon assorbibili contenente un sale di calcio ed un sale di alluminio
CA2335308A1 (en) Protease containing hairball remedy and use thereof
CA2322878A1 (en) Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
BR9811548A (pt) Secreções maternas imunes e seu uso no tratamento e/ou profilaxia de condições do corpo humano
WO1999012552A8 (en) 9a-AZALIDES AS VETERINARY ANTIMICROBIAL AGENTS
CA2301872A1 (en) 8a-azalides as veterinary antimicrobial agents
BR9908143A (pt) Composições para a redução da atividade enzimática, utilização de ácido dissuccìnico de etileno diamina, utilização de um agente de complexação, artigo absorvente, desodorante, e utilização de composição
DE69941459D1 (de) Verfahren zur herstellung von essbaren zusammenstellungen mit antibakteriellen wirkstoffen
Pellegrin et al. Response to infection in patients with acute leukemia during remission induction treatment: Ceftazidime versus cefotaxime+ tobramycin.
WO2002038103A3 (en) Probiotic compositions and methods against bacterial infection in livestock animals
EP1779853A3 (en) 9a-azalides as veterinary antimicrobial agents
CA2170289A1 (en) A method of treating liver disease and like indications with vasodilating agents
TH54151B (th) การรักษาการติดเชื้อด้วยเอนไซม์
RU95102208A (ru) Средство лечения эндометрита у коров
TH49215B (th) องค์ประกอบซึ่งประกอบรวมด้วยเอนไซม์สำหรับรักษาการติดเชื้อของทางเดินอาหาร

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25A Requested transfer of rights approved

Owner name: ELI LILLY AND COMPANY (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 04/10/2016, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved
B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/12/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 08/12/2020